SYNTARA LIMITED (SNT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SNT

SNT - SYNTARA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.031

05 Dec
2025

-0.001

OPEN

$0.03

-3.13%

HIGH

$0.03

705,756

LOW

$0.03

TARGET
$0.06 93.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
SNT: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 0.5 - 0.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-0.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx1.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.1 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-118.44 %
Return on Invested Capital xxxxxxxxxxxxxxx-117.96 %
Return on Assets xxxxxxxxxxxxxxx-77.03 %
Return on Equity xxxxxxxxxxxxxxx-118.44 %
Return on Total Capital xxxxxxxxxxxxxxx-183.11 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx15 M
Price To Book Value xxxxxxxxxxxxxxx5.38

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx19 M
Research & Development xxxxxxxxxxxxxxx10 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

02/10/2025

1

Speculative Buy

$0.06

93.55%

Bell Potter highlights Syntara's compelling Phase 2a results for amsulostat in myelofibrosis. Patients with limited prior treatment response showed significant symptom improvement and spleen size reductions.

Half of the patients achieved a -50% or greater reduction in Total Symptom Score (TSS) and four of nine evaluable patients recording a greater than (or equal) -25% spleen reduction.

The broker believes the consistency of benefits underlines the drug’s potential and supports progression to late-stage trials.

Discussions with regulators are planned for 1H 2026 ahead of a Phase 2b trial expected to commence later in 2026. 

No material forecast changes are made, and the broker maintains a 6c target and a Speculative Buy rating.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.50 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.20 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

26/11/2025

1

Buy

$0.19

512.90%

Syntara provided an update on its early topical scar programs SNT-6302 and SNT-9465, which Canaccord Genuity finds "intriguing."

The broker is still valuing the assets at zero, given early data and unclear reimbursement and despite promising trial/imaging advances. 

If mid-2026 results are IND (investigational new drug)-enabling, the broker sees that as the right point to reassess. This would likely be in the context of a licensing or partnering deal since the company probably won’t advance development alone.

Buy. Target unchanged at 19c.
Access Extra Coverage Research History >

SNT STOCK CHART

FNArena News on SNT

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest